FierceHealthcare names COTA, Inc. as one of its 2020 “Fierce 15” Companies

January 13, 2020

Boston, MA – January 13, 2020 – COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, today announced that it has been named by FierceHealthcare as one of the 2020 Fierce 15 companies, designating it as one of the most promising healthcare companies in the industry.

The very nature of what COTA employees do requires passion and ferocity as they try to improve cancer care and research. Clinicians spend up to 35% of their day entering data into EHRs, but without the right technology to extract and organize this data, it can not be used in a meaningful way. COTA was created by a group of oncologists, engineers, and data scientists to fix this problem.

“We are proud to be recognized as one of the Fierce 15 companies of 2020, and truly believe that as COTA succeeds, cancer care will be transformed,” said Mike Doyle, CEO of COTA. “With only 3-5% of the population living with cancer involved in clinical trials, many patients are underrepresented by existing published results. We are actively working with life science partners and the FDA to advance the use of RWD to ensure that cancer research represents broader cohorts of patients than those who would traditionally be included in a clinical trial.”

The company has adopted a multi-pronged approach partnering with providers, life science companies, and payers to bring clarity to this incredibly complex disease. Their technology platform provides clinical teams with the right information to ultimately make better decisions at the point of care and can aid in the understanding of how to treat different cancers in the most cost-effective manner, ultimately reducing the financial burden on patients.

Increasingly, COTA’s regulatory-grade RWD is being used in clinical trials to develop external control arms (also known as synthetic control arms) with the goal of obviating the need for enrolling concurrent controls in certain circumstances. This has the potential to reduce the time and cost of the clinical development effort which can take as many as 10 years and cost hundreds of millions of dollars. Most importantly, it benefits patients, because no patient wants to receive a mediocre standard-of-care treatment or placebo when alternatively, there is an opportunity to receive a promising experimental agent. 

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is FierceHealthcare’s second annual Fierce 15 selection and represents many corners of the industry from health IT to health payers to precision medicine.

“This crop of Fierce15 winners are rethinking the way health care is delivered and pushing the needle forward when it comes to the consumer experience,” said Tina Reed, FierceHealthcare’s executive editor.

An internationally recognized daily report reaching a network of over 120,000 healthcare industry professionals, FierceHealthcare provides subscribers with an authoritative analysis of the day’s top stories. This year FierceHealthcare evaluated hundreds of companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as strength of its technology, partnerships, venture backers and its innovative approach to solving some of the most complex and longstanding problems in the health industry.

About FierceHealthcare

FierceHealthcare is the healthcare industry’s daily monitor, an email newsletter and web resource providing the latest news and resources related to healthcare organizations and providers, policies & regulations, healthcare reform and more. More than 120,000 top healthcare professionals rely on FierceHealthcare for an insider look on top stories. Signup is free at

About COTA, Inc.

Founded by doctors, engineers and data scientists, COTA is committed to bringing a patient first approach to cancer care through the use of real-world evidence. The Company organizes fragmented, often hidden data from the real world to provide clarity in cancer care. Combining clinical expertise in cancer with proprietary technology and advanced analytics, COTA helps inform decisions and action in oncology. COTA partners with providers, payers, and life science companies to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to make better decisions with the right data, visit

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.